[{"id":"958b0570-f348-4122-aba8-67724c61c6ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04460456","created_at":"2021-01-18T21:26:47.512Z","updated_at":"2024-07-02T16:36:08.027Z","phase":"Phase 1","brief_title":"A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors","source_id_and_acronym":"NCT04460456","lead_sponsor":"Silverback Therapeutics","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • pertuzumab zuvotolimod (SBT6050)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-06-30"}]